No Association of the NF-κB1 −94INS/Delattg Promoter Polymorphism with Relapse-Free and Overall Survival in Patients with Squamous Cell Carcinomas of the Head and Neck Region

Abstract

The transcription factor, nuclear factor-κB (NF-κB) is known to play a major role in immune response, inflammation and, via apoptosis and proliferation, also in oncogenesis. Transcription of NFKB1, which encodes the subunit p50/p105 of NF-κB, seems to be influenced by an insertion/deletion polymorphism in its promoter region. Accordingly, the goal of this study is to investigate whether this polymorphism can serve as a putative prognostic marker in patients with Squamous Cell Carcinomas of the Head and Neck region (HNSCC). The prognostic value of the −94ins/delATTG NFKB1 promoter polymorphism was analyzed in an unselected series of patients treated with curative intent for HNSCC, including all tumor stages with different therapeutical regimens. Genotyping was performed by means of pyrosequencing, using DNA from paraffin-embedded tissue samples from 364 patients with a median follow-up of 61 (2-143) months. The various genotypes were correlated with relapse-free and overall survival, as well as risk, compared to healthy volunteers. The NFKB1 polymorphism was not related to risk of HNSCC. Kaplan-Meier curves revealed no significant association between the −94ins/delATTG alleles and survival or disease progression of patients with HNSCC. In conclusion, the results suggest that the investigated NFKB1 promoter polymorphism has no prognostic impact on risk or clinical course in HNSCC.

Keywords

NFKB1 -94ins/delATTG polymorphism prognostic marker HNSCC

References

Baldwin

. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107:241–6.

Camp

Minnich

. Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 2004; 199:249–58.

Cao

Karin

. NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003; 8:215–23.

Dajee

Lazarov

Zhang

. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003; 421:639–43.

Takayama

Inoshima

. Gene transfer of inhibitor kappaB in human lung cancer cell line NCI-H460 inhibits tumorigènesis and angiogenesis in vivo. Anticancer Res 2005; 25:69–77.

Riemann

Becker

Struwe

Rubben

Eisenhardt

Siffert

. Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther 2007; 45:423–30.

Salvatore

Camarda

Maggi

Goso

Manzini

Binaschi

. NF-kappaB activation contributes to anthracycline resistance pathway in human ovarian carcinoma cell line A2780. Int J Oncol 2005; 27:799–806.

Tracey

Perez-Rosado

Artiga

. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2005; 206:123–34.

Adamzik

Frey

Rieman

. Insertion/deletion polymorphism in the promoter of NFKB1 influences severity but not mortality of acute respiratory distress syndrome. Intensive Care Med 2007; 33:1199–203.

10.

Karban

Okazaki

Panhuysen

. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13:35–45.

11.

Lin

Liu

Yeh

Lui

Chang

. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 2006; 243:47–54.

12.

Riemann

Becker

Struwe

. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics 2006; 16:783–8.

13.

Gauderman

Morrison

. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies. http://hydra.usc.edu/gxe 2006.

14.

Karin

Cao

Greten

. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002; 2:301–10.

15.

Lin

Lee

Lin

Chen

Chang

. Areca (betel) nut extract activates mitogen-activated protein kinases and NF-kappaB in oral keratinocytes. Int J Cancer 2005; 116:526–35.

16.

Vermeulen

Notebaert

Vanden

Haegeman

. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol 2002; 64:963–70.

17.

Bharti

Aggarwal

. Nuclear factor-kappa B and cancer: Its role in prevention and therapy. Biochem Pharmacol 2002; 64:883–8.

18.

Ondrey

Dong

Sunwoo

. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999; 26:119–29.

19.

Chan

Boyle

Yang

. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59:991–4.

20.

Kourelis

Sotiropoulou-Bonikou

Vandoros

Repanti

Varakis

Goumas

. Coordinated upregulation of COX-2 and NF-kappaB is a steady feature of laryngeal carcinogenesis. ORL J Otorhinolaryngol Relat Spec 2007; 69:181–9.

21.

Santhi

Sebastian

Varghese

Prakash

Pillai

. NF-kappaB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins. Exp Mol Pathol 2006; 81:123–30.

22.

Fitzpatrick

. Inflammation, carcinogenesis and cancer. Int Immunopharmacol 2001; 1:1651–67.

23.

Nishimura

Yanoma

Mizuno

Kawakami

Tsukuda

. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999; 90:1152–62.